Latest Safety News

Bhagwan Marine Limited has reported record financial results for FY25, driven by strong growth across its core marine services and new sectors. The company also declared its inaugural fully franked dividend, signaling confidence in its strategic direction.

RemSense Technologies posted a 107% revenue surge to $3.44 million in FY2025 alongside a 67% reduction in net loss, driven by operational efficiencies and strong client demand. The company achieved positive cash EBITDA and strengthened its global footprint with Tier 1 clients.

Noxopharm Limited reported a 36.5% increase in its annual loss to $4.88 million as it progressed preparations for its SOF-SKN™ clinical trial and secured $2.6 million through convertible notes. The biotech continues to invest heavily in its inflammation and oncology drug pipeline while managing liquidity and strategic partnerships.

Wellard Ltd posts a net profit turnaround in FY2025 despite fleet downsizing, sells its last vessel, and plans to delist from the ASX while returning substantial capital to shareholders.

Cynata Therapeutics reported a $9.39 million net loss for FY2025, slightly improved from the prior year, while progressing multiple clinical trials with key results expected in 2026. The company maintains a solid cash position and funding runway through mid-2026, supported by recent capital raises and an equity subscription agreement.

BTC Health Limited reported a robust 25% revenue increase in FY25, driven by strategic contract wins and expanded product offerings across critical medical sectors. The company’s positive EBITDA and new partnerships position it well for continued growth in FY26.

NEXTDC’s FY25 results reveal robust financial growth driven by surging AI and cloud demand, alongside a strategic joint venture to expand its Western Sydney data centre footprint.

NEXTDC Limited reported a 6% rise in FY25 revenue and underlying EBITDA, offset by a widened loss due to a $2.9 billion debt refinancing. The company’s strategic expansion in AI-ready data centres and a strengthened $6.4 billion debt facility position it for significant growth.

Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.

Bisalloy Steel Group reported steady revenue but strong profit growth and a significant dividend increase for FY25, while outlining ambitious expansion plans for FY26.

Bisalloy Steel Group Limited reported a 24.4% rise in profit after tax to $19.6 million for FY25, driven by strong Armour & Protection steel sales and international growth. The company declared a 16.5 cents per share fully franked final dividend, up 43.5% from last year, while advancing key growth initiatives in Asia and sensor technology.

Icetana Limited posted a $2.9 million net loss for FY2025, with revenues down 49% due to lower non-recurring sales, while recurring SaaS income grew. The company secured a $3.6 million strategic partnership with SoftBank Robotics, strengthening its foothold in Japan.